

## Sonelokimab

Cat. No.:	HY-P99397
CAS No.:	1414386-05-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research <sup>[1][2]</sup> .	
IC <sub>50</sub> & Target	IL-17A	IL-17F

### REFERENCES

[1]. Kim A Papp, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. *Lancet*. 2021 Apr 24;397(10284):1564-1575.

[2]. Martin A Rossotti, et al. Immunogenicity and humanization of single-domain antibodies. *FEBS J*. 2022 Jul;289(14):4304-4327.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA